---
title: "UroGen Pharma to Present at Guggenheim Securities Emerging Outlook Biotech Summit"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274816846.md"
datetime: "2026-02-04T13:00:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274816846.md)
  - [en](https://longbridge.com/en/news/274816846.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274816846.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274816846.md) | [繁體中文](https://longbridge.com/zh-HK/news/274816846.md)


# UroGen Pharma to Present at Guggenheim Securities Emerging Outlook Biotech Summit

UroGen Pharma Ltd. will present at the Guggenheim Securities Emerging Outlook: Biotech Summit on February 12, 2026, at 2:30 PM ET in New York, NY. The event will feature a fireside chat and 1x1 investor meetings, with a webcast available on UroGen’s corporate website. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9648319-en) on February 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [UroGen Pharma Ltd. (URGN.US)](https://longbridge.com/en/quote/URGN.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Clene 2025 net loss narrows as expenses fall](https://longbridge.com/en/news/278880252.md)
- [Prelude Therapeutics reports $99.5 mln net loss for 2025](https://longbridge.com/en/news/278542482.md)
- [Century Therapeutics 2025 net loss narrows beating estimates](https://longbridge.com/en/news/278880556.md)
- [Capricor Theraputics Q4 revenue falls to zero, net loss widens](https://longbridge.com/en/news/278939139.md)
- [Incannex Healthcare Prices $10 Mln Potential Offering Of Shares And Warrants; Stock Down](https://longbridge.com/en/news/278896600.md)